UPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Teva Pharma (TEVA) PT Lowered to $14 at Susquehanna
November 6, 2017 7:25 AM ESTSusquehanna lowered its price target on Teva Pharma (NYSE: TEVA) to $14.00 (from $20.00) while maintaining a Positive rating.
Analyst Andrew Finkelstein notes Q3 showed further challenges.
... MoreTeva Pharma (TEVA) PT Slashed to $10 at Cantor Fitzgerald
November 2, 2017 1:39 PM EDTCantor Fitzgerald analyst Louise Chen lowered her price target on Teva Pharma (NYSE: TEVA) to $10.00 (from $17.00) while maintaining a Neutral rating following Q3 miss and lower guide.
Chen thinks the company has some meaningful headwinds which need to be addressed before the... More
Teva Pharma (TEVA) Plunges to Fresh Low, Down 16%
November 2, 2017 9:33 AM EDTTeva Pharma (NYSE: TEVA) Plunges to Fresh Low, Down 16%
... More